Public Company News
Soundcore Liberty 5: Revolutionizing Voice-Canceling with Adaptive ANC 3.0 and Dolby Audio
Top 3 Global Wireless Audio Brand [1] Unveils Next-Gen Travel-Ready Earbuds HO CHI MINH CITY, Vietnam, May 26, 2025 /PRNewswire/ -- Soundcore, the premium audio brand under Anker Innovations and ranked third globally in wireless headphone shipments, today launched its groundbreaking product, th...
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
EDAN Highlights Commitment to Global Health at GHF 2025 Satellite Symposium, a Side Event of the World Health Assembly
GENEVA, May 25, 2025 /PRNewswire/ -- Edan Instruments, Inc.
Mindray Debuts Next-Generation BeneVision V Series Patient Monitoring System at Euroanaesthesia 2025
SHENZHEN, China, May 25, 2025 /PRNewswire/ -- Mindray
Soundcore Liberty 5: Revolutionizing Voice-Canceling with Adaptive ANC 3.0 and Dolby Audio
Top 3 Global Wireless Audio Brand[1] Unveils Next-Gen Travel-Ready Earbuds SINGAPORE, May 25, 2025 /PRNewswire/ -- Soundcore, the premium audio brand under Anker Innovations and ranked third globally in wireless headphone shipments, today launched its groundbreaking product, the Liberty 5 in Si...
COMPUTEX 2025: MiTAC Powers Sustainable AI Data Centers with New Server & Cooling Tech
TAIPEI, May 24, 2025 /PRNewswire/ -- At COMPUTEX 2025, MiTAC Computing Technology Corp., a subsidiary of MiTAC Holdings Corp. (TWSE: 3706), unveiled its bold new vision: from hardware provider to full-solution AI and data center innovator. With future-ready solutions covering AI training and infe...
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
* YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] * Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled syringes (20mg & 80mg); Expanded interchangeabilit...
/DISREGARD RELEASE: Celltrion/
We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued21-May-2025 over PR Newswire. ...
TWSC Debuts at COMPUTEX 2025: Empowering AI with Full-Stack Storage Solutions
TAIPEI, May 23, 2025 /PRNewswire/ -- From May 20 to 23, 2025, TWSC
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
SHANGHAI, May 23, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clini...
Tongcheng Travel 2025Q1 Secures Foothold in the Mass Travel Market Revenue Grows 13.2% Yoy to RMB4.4 Billion
Rising Travel Spending Boosts Core OTA Business Growth AI Empowers High-Quality Development Across the Travel Industry Chain HONG KONG, May 23, 2025 /PRNewswire/ -- Tongcheng Travel Holdings Limited ("Tongcheng Travel" or the "Company", together with its subsidiaries the "Group", stock code: 0...
NYSE Content Advisory: Pre-Market update + Hinge Health, MNTN pop double digits in trading debuts
NEW YORK, May 23, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on May 23rd * Dig...
WGC2025 | ENN Leverages "Intelligence + Low Carbon" to Pioneer a New Paradigm for Sustainable Energy Development
LANGFANG, China, May 23, 2025 /PRNewswire/ -- From May 19 to 23, 2025, the 29th World Gas Conference (WGC2025), hosted by the International Gas Union (IGU), convened inBeijing. As the premier global event in the energy sector, WGC2025 attracted leading companies and industry experts from around t...
Eason Technology Limited Receives Notification from NYSE Regarding Delayed Form 20-F Filing
HONG KONG, May 23, 2025 /PRNewswire/ -- Eason Technology Limited ("Eason
Technology" or the "Company") (NYSE:DXF
Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting
CHENGDU, China, May 23, 2025 /PRNewswire/ -- The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six cl...
Tuniu Announces Receipt of Minimum Bid Price Notice from Nasdaq
NANJING, China, May 23, 2025 /PRNewswire/ -- Tuniu Corporation (Nasdaq: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company inChina, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market L...
MINISO Group Announces March Quarter 2025 Unaudited Financial Results
Revenue grew 18.9 % year over year Significant sequential improvement of same-store sales(1) in MINISO mainland China for March Quarter Gross margin reached 44.2%, up 0.8 ppt year over year Adjusted EBITDA increased 7.5% year over year to RMB1,037.3 million Shareholder returns reached around RM...
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial4 ST. GALLEN, Switzerland, May 23, 2025 /PRNewswi...
Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025
* ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01 t...
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics,announced that NEFECON® has been included in the "Clin...
Week's Top Stories
Most Reposted
vVardis Raises $175 Million Ahead of NYSE IPO: NYSE Content Update
[Picked up by 1183 media titles]
2026-11-13 22:11Cision Introduces AI-Powered Cision Intelligence to Help Brands See More and Act with Confidence
[Picked up by 1170 media titles]
2026-11-12 23:00The NYSE Welcomes vVARDIS as a Publicly Listed Company
[Picked up by 1168 media titles]
2026-11-14 13:23Cyient, 3-GIS Partner to Help Telecom and Utility Operators Turn Network Data into Operational Control
[Picked up by 1154 media titles]
2026-11-11 22:00Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1143 media titles]
2026-11-09 21:00